Sanofi and DN­Di aim to elim­i­nate sleep­ing sick­ness in Africa with promis­ing Ph II/III re­sults for new drug

The Drugs for Ne­glect­ed Dis­eases ini­tia­tive (DN­Di) and Sanofi to­day said that their po­ten­tial sleep­ing sick­ness treat­ment saw suc­cess rates of up to 95% from a Phase II/III study in­ves­ti­gat­ing the safe­ty and ef­fi­ca­cy of sin­gle-dose aco­z­i­bo­role.

The po­ten­tial­ly trans­for­ma­tive treat­ment for sleep­ing sick­ness would main­ly be tar­get­ed at African coun­tries, ac­cord­ing to da­ta pub­lished to­day in The Lancet In­fec­tious Dis­eases med­ical jour­nal. The clin­i­cal tri­al was led by DN­Di and its part­ners in the De­mo­c­ra­t­ic Re­pub­lic of the Con­go (DRC) and Guinea, with the au­thors not­ing:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER